PRESS RELEASE published on 02/21/2024 at 14:15, 8 months 28 days ago Biotricity Strengthens its Foundation for Growth, Achieves Lower Cost of Sales, Expanding Margins of 73% and Increased Device Sales, for Third Quarter of Fiscal Year 2024 Biotricity Inc. reports Q3FY24 financial results showing topline growth, increased subscription revenue, improved margins, lower costs, and a stronger path to breakeven in the remote cardiac monitor sector of consumer healthcare Healthcare Biotricity Inc. Q3FY24 Financial Results Subscription Revenue Remote Cardiac Monitor
BRIEF published on 02/21/2024 at 14:15, 8 months 28 days ago Biotricity Inc. announces growth with a significant increase in subscriptions for the third quarter of the 2024 fiscal year Financial Results Revenue Growth Biotricity Inc. Remote Cardiac Monitoring Technological Subscriptions
PRESS RELEASE published on 02/19/2024 at 14:00, 9 months 1 day ago Biotricity to Host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21st Biotricity Inc. to host Third Quarter FY 2024 Financial Results and Business Update Call on February 21, 2024, featuring Founder Dr. Waqaas Al-Siddiq and CFO John Ayanoglou. Event details and webcast information provided Financial Results Business Update Biotricity Inc. Investor Call Remote Health Monitoring
PRESS RELEASE published on 02/14/2024 at 14:00, 9 months 6 days ago Biotricity Advances Towards Breakeven Milestone - Set to Announce Record Margins and Operational Efficiency for Third Quarter of Fiscal Year 2024 Biotricity Inc. continues its shift to subscription-based revenue, emphasizing margin improvement and operational efficiency enhancements. Company to announce Third Quarter Fiscal 2024 Results on February 20, 2024 Operational Efficiency Biotricity Inc. Subscription-based Revenue Margin Improvement Third Quarter Fiscal 2024 Results
PRESS RELEASE published on 01/23/2024 at 14:15, 9 months 28 days ago Biotricity Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 billion Heartbeats Biotricity Inc. (NASDAQ:BTCY) has announced the expansion of its Cardiac AI Cloud platform, aiming to develop predictive monitoring to identify issues before they occur, supporting earlier interventions, and reducing healthcare costs. The company's goal is to build comprehensive AI models for improved diagnoses and interventions, having analyzed over 360 billion heartbeats and helped diagnose over 200,000 patients. The development of large data models is crucial for supporting the intermittent nature of cardiac issues and the noisy data arising from ambulatory monitoring, and for helping cardiologists service more patients. The company's effort in building a comprehensive Cardiac AI Cloud platform aims to make cardiac care accessible, affordable, and scalable, thus providing necessary support and assistance to healthcare professionals. For more information, visit www.biotricity.com. Biotricity Inc. Cardiac AI Cloud Platform Predictive Monitoring Healthcare Costs Comprehensive AI Models
Published on 11/21/2024 at 13:30, 17 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 17 minutes ago Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 47 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 47 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 47 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 12:35, 1 hour 12 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 32 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 49 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 27 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 2 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 2 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo